• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Telix Pharmaceuticals Limited - American Depositary Shares (NQ:TLX)

    9.890 -0.170 (-1.69%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Telix Pharmaceuticals Limited - American Depositary Shares

    < Previous 1 2 3 4 5 6 7 Next >
    News headline image
    Telix H1 2026 Results: Investor Webcast Notification
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    TLX591-Tx ProstACT SELECT Study Published in Cancers Journal
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    FDA Alignment to Advance ProstACT Global Phase 3 Trial
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix and United Imaging Announce Strategic Theranostics Collaboration
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    TLX101-Px (Pixlumi®) MAA Accepted in Europe
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix and Regeneron Announce Strategic Radiopharma Collaboration
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Regeneron and Telix Announce Strategic Radiopharma Collaboration
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    FDA Accepts NDA for TLX101-Px (Pixclara®)
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Strengthens Board with Additional Director Appointments
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Appoints David Gill as Non-Executive Director
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Investor Education Webinar
    The Future of Prostate Imaging: What do physicians want? 
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix to Participate in Oppenheimer and TD Cowen Conferences
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.